Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., . . . Katayama, R. (2017). Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nature communications, 8(1), 14768. https://doi.org/10.1038/ncomms14768
Citácia podle Chicago (17th ed.)Uchibori, Ken, Naohiko Inase, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, Yasushi Okuno, Naoya Fujita, a Ryohei Katayama. "Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-mutated Non-small-cell Lung Cancer." Nature Communications 8, no. 1 (2017): 14768. https://doi.org/10.1038/ncomms14768.
Citácia podľa MLA (8th ed.)Uchibori, Ken, et al. "Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-mutated Non-small-cell Lung Cancer." Nature Communications, vol. 8, no. 1, 2017, p. 14768, https://doi.org/10.1038/ncomms14768.